Targeting aberrant glycosylation holds huge potential for cancer research [50–52], and we envisage that both GALNT7, and its associated glycans (particularly the cancer-associated Tn antigen) hold huge promise in prostate cancer therapy that needs to be explored. The gene discussed is GALNT7; the disease is prostate carcinoma.